| Type | Title | Date Released | |
|---|---|---|---|
6-K | NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data | ||
6-K | NeuroSense Enters Strategic Collaboration to Advance Revenue-Generating Supply of PrimeC for ALS Patients | ||
6-K | NeuroSense Files U.S. Patent Application for Traumatic Brain Injury Treatment with PrimeC | ||
6-K | NeuroSense Secures Nasdaq Hearing Date and Outlines Regulatory Milestones for PrimeC | ||
6-K | NeuroSense Regains Nasdaq Minimum Bid Price Compliance and Appeals MVLS Delisting Determination | ||
6-K | NeuroSense Provides H1 2026 Business Update, Highlighting PrimeC Regulatory and Clinical Progress | ||
6-K | NeuroSense Therapeutics Announces 1-for-20 Reverse Share Split | ||
6-K | NeuroSense Therapeutics Shareholders Approve Reverse Share Split | ||
6-K | NeuroSense Therapeutics CEO Updates Shareholders on PARAGON Phase 3 Study, Regulatory Strategy, and Nasdaq Compliance | ||
6-K | NeuroSense Completes PrimeC Pre-NDS Process and Targets December 2026 Filing with Health Canada | ||
EFFECT | Form EFFECT | ||
6-K | NeuroSense Therapeutics Ltd. Schedules Special Meeting to Vote on Reverse Share Split |
